KELLY LACLAIR: Open Payments
NPI 1053736645 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,012 in 112 payments from 18 companies in 2025. Trend: 2023 $24 · 2024 $137 · 2025 $2,012
Food & beverage: $2,012
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 40 | $542 |
| UCB, Inc. | 9 | $208 |
| Novartis Pharmaceuticals Corporation | 12 | $200 |
| Lundbeck LLC | 10 | $189 |
| Lilly USA, LLC | 8 | $180 |
| Eisai Inc. | 7 | $139 |
| SK Life Science, Inc. | 5 | $115 |
| ARGENX US, INC. | 3 | $78 |
| ACADIA Pharmaceuticals Inc | 4 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $58 |
Products named: UBRELVY, KESIMPTA, AMYVID, QULIPTA, Leqembi, VYEPTI, REXULTI, Briviact.
Industry payments across AL — which companies pay providers there.
